US vaccine overhaul unnerves investors as sceptics seize advisory posts
Vaccine businesses seen as valuable parts of pharma groups but government hostility could deter future developments
Related reading
America’s unfortunate backward step on vaccines
2025 has been a good year for immunisation science, but not in the US
A test for global public health
The decline in funding for vaccinations poses a worldwide threat
Investors are shaken, but not yet stirred
Amid global turmoil, markets are focused on the hit to economic fundamentals
How US anti-vaxxers found they were not immune to pushback
Recent setbacks for the movement signal a potential turning point for the vaccine makers as the market picks up
As measles spreads, old vaccination canards do too
For as long as there have been vaccines, there has been passionate opposition to them
Europe races to placate pharma as Donald Trump turns up the pressure
Tariff deals with the US have bought time but investment momentum is elsewhere